Primary Outcome Measures Rate of patients who decide to enroll in a mesothelioma medical study. [ Time Frame: 3 months ] Number of mesothelioma patients who remain in clinical trial until completion. [ Time Frame: 12 months ] Inclusion Criteria Must have a medical diagnosis of mesothelioma that has been confirmed by a physician. Aged ≥ 18 years[…]
Full Archive
YAP/TEAD Inhibitor is Showing Promising Results for Mesothelioma and NF2-Mutant Cancers
A YAP/TEAD inhibitor is showing promising results for people with mesothelioma and other cancers. The inhibitor, known as VT3989, was well tolerated and had good anti-tumor effects in cancer patients with mesothelioma and NF2 mutations. Results were recently published from the first human study. Seven of 69 patients had radiological[…]
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Primary Outcome Measures Phase 1 (Dose Escalation): Incidence of adverse events [ Time Frame: From CTX131 infusion up to 28 days post-infusion ] Defined as dose-limiting toxicities Phase 2 (Cohort Expansion): Objective response rate (ORR) [ Time Frame: From CTX131 infusion up to 60 months post-infusion ] ORR based on Independent Review Committee (IRC) assessment, defined as the[…]
Impact on Survival When People Have a Second Cancer in Addition to Mesothelioma
Researchers decided to look at the relationship between having mesothelioma in addition to a second cancer and their impact on survival. Researchers found that a second cancer did not affect survival for most patients with mesothelioma, but for patients with a specific type of mesothelioma, survival was affected. Mesothelioma is[…]
Cytoreductive Surgery and Chemotherapy Improved for Mesothelioma
Improvements have been made for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). This treatment combination is typically performed on people with cancers in the abdominal region. One such cancer is peritoneal mesothelioma. Peritoneal mesothelioma is a cancer of the lining of the abdomen caused by asbestos exposure. Peritoneal mesothelioma is[…]
Keytruda Helps Improve Survival for Mesothelioma When Used Alongside Chemotherapy
Keytruda is showing promising results for the treatment of pleural mesothelioma. Researchers found that the combination of Keytruda (pembrolizumab) and chemotherapy lead to a better survival in patients versus chemotherapy alone. Mesothelioma is a hard-to-treat cancer with no cure. It can be found in the linings of the lungs, abdomen,[…]
Mesothelioma Global Impact Study
A study looking at the global impact of mesothelioma was recently published. Researchers examined age, sex, and geographic locations to see the risk of asbestos at the population level. It was discovered that Northern Europe, Australia, and New Zealand had the highest rates of mesothelioma. The age standardized rate of[…]
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma (Immuno-MESODEC)
Primary Outcome Measures Proportion of patients that experienced (S)AEs possibly, probably or definitely related to pemetrexed and/or cisplatin/carboplatin and/or atezolizumab and/or WT1/DC vaccination [ Time Frame: through study completion, an average of 2 years ] The relationship of an AE to the investigational agents will be determined by the Investigator as either related or[…]
BAP1 and Mesothelioma Risk
Researchers have found at least one way that asbestos causes mesothelioma. The disease is linked to the HMGB1 protein. Researchers looked at a mesothelioma epidemic in Türkiye, noting that in some families, up to 50 percent develop mesothelioma. Family members passed the likelihood of mesothelioma from generation to generation. Families[…]
Accelerated Hypofractionated Radiotherapy for Mesothelioma
A recent study from Italy found that accelerated hypofractionated radiotherapy could be an effective treatment for mesothelioma. This is good news for people suffering from the rare and aggressive cancer. The patients in the study had higher chances of living longer while also having a lower risk of the disease[…]
